ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1718

Parenchymal INFγ Response Regulates Murine Lupus Nephritis

Minjung Kim1, Anthony Marinov1, Mark Shlomchik2 and Jeremy Tilstra2, 1University of Pittsburgh, Pittsburgh, 2University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: Animal Model, immunology, Lupus nephritis, Mouse Models, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Animal Models Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE. Interstitial infiltrates, specifically T cells, are major predictors of disease outcomes. We recently determined that kidney-infiltrating T cells (KITs) are suppressed after kidney infiltration and exhibit an exhausted phenotype. Notably, the kidneys of nephritic lupus-prone (MRL.Faslpr) mice upregulate PD-L1, which we hypothesize is one mechanism inducing KIT suppression. IFNγ is the major inducer of PD-L1 and therefore, given the known role of IFNγ in lupus nephritis, we postulated that IFNγ induces a protective program in the kidneys of lupus-prone mice, in direct contrast to the proinflammatory role of IFNγ in the hematopoietic compartment.

Methods: MRL.Faslpr mice develop autoantibodies, proteinuria, dermatitis, and glomerulonephritis. Others have previously shown that global IFNγ receptor deficiency (IFNγR-/-) ameliorates disease in this mouse model. To determine if IFNγ signaling on parenchymal cells regulates disease, we generated bone marrow chimeras by transferring congenically labeled WT immune cells into either wild-type (WT) or IFNγR-/- MRL.Faslpr recipients. If our hypothesis is correct, then the IFNγR-/- recipients would have more severe disease than their WT counterparts. Chimerization occurred at 4-6 weeks of age, female and male mice were analyzed for disease pathology at 23 and 27 weeks post-chimerization respectively. Analysis included proteinuria, renal histology for both interstitial and glomerular disease, dermatitis, autoantibody production, and immune cell activation. Survival analysis was performed on female mice. Additional analysis focused specifically on T cell phenotypes.

Results: IFNγR-/- MRL.Faslpr recipient mice exhibited more severe and rapid disease onset than WT recipient controls. While proteinuria was not different between the two groups, the IFNγR-/- recipients had more severe glomerulonephritis (p< 0.005) and interstitial disease (p< 0.001). Consistent with these findings, IFNγR-/- recipients had reduced survival (p< 0.05). As expected, IFNγR deficiency resulted in reduced PD-L1 expression. When examining infiltrates, KITs isolated from IFNγR-/- recipients exhibited increased expression of Tim3 and PD-1, further supporting the idea that the parenchymal tissue response to inflammation can alter the phenotype of infiltrating cells.

Conclusion: These experiments support the notion of a complex interplay between immune cells and the target organ they infiltrate. Specifcally, parenchymal IFNγR signaling results in upregulation of protective mechanisms which reduce kidney disease and alter T cell phenotypes. This contrasts with global IFNγR-/- which results in ameliorated kidney disease. Overall, these finding argues that suppression of IFNγ, and possible other inflammatory mediators, may have differential effects on specific cell lineages and that global suppression of IFNγR may have both positive and negative effects on disease pathogenesis. This will need to be considered when devising targeted therapies.


Disclosures: M. Kim, None; A. Marinov, None; M. Shlomchik, None; J. Tilstra, None.

To cite this abstract in AMA style:

Kim M, Marinov A, Shlomchik M, Tilstra J. Parenchymal INFγ Response Regulates Murine Lupus Nephritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/parenchymal-inf%ce%b3-response-regulates-murine-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/parenchymal-inf%ce%b3-response-regulates-murine-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology